MedTrace Logo

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Conditions

Interventions

DRUG

[64Cu]FBP8

Injection of Copper-64 radiopeptide to detect thrombosis

DEVICE

PET/MR

Whole body imaging using Siemens mMR PET/MR scanner

PROCEDURE

Blood Collection

A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry

PROCEDURE

Electrocardiogram

A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Ciprian Catana, PhD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830320 on ClinicalTrials.gov